| 摘要 |
he application relates to compounds of formula (I), wherein A is an optionally substituted, ring system provided that the -CH(R3)N(R2)B-R1 and -OD groups are positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom positioned ortho to the -OD linking group (and therefore in the 3-position relative to the -CHR3NR2- linking group) is not substituted; B is an optionally substituted ring system; R1 is positioned on ring B in a 1,3 or 1,4 relationship with the -CH(R3)N(R2)- linking group and is as defined in the description; R2 is hydrogen, C1-6alkyl, optionally substituted by hydroxy, cyano or trifluoromethyl, C2-6alkenyl (provided the double bond is not in the 1-position), (C2-6alkynyl (provided the triple bond is not in the 1-position), phenylC1-3alkyl or pyridylC1-3alkyl; R3 is hydrogen, methyl or ethyl; D is hydrogen, an optionally substituted 5-7 membered carbocyclic ring containing one double bond, C1-3alkyl substituted by an optionally substituted 5-7 membered carbocyclic ring containing one double bond or D is of the formula -(CH2)nCH(R4)C(R5)=C(R6)R7 and N-oxides of -NR2 where chemically possible; and S-oxides of sulphur containing rings where chemically possible; and pharmaceutically acceptable salts and in vivo hydrolysable esters and amides thereof; excluding 4-[5-carboxy-2-hydroxybenzylamino]benzoic acid, 4-[2,5-dihydroxybenzylamino]benzoic acid, 5-[2-hydroxybenzylamino]-2-hydroxybenzoic acid, 3-[2,5-dihydroxybenzylamino]benzoic acid, 4-[2,5-dihydroxybenzylamino]benzenecarboxamide, 3-[2-hydroxybenzylamino]benzoic acid, 4-[2,5-dihydroxybenzylamino]-2-hydroxybenzoic acid, 4-[hydroxybenzylamino]-2-hydroxybenzoic acid and 4[2-hydroxybenzylamino]benzoic acid. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
|
